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Overview
Recent studies have shown that single-dose combination therapy with three currently
approved antifilarial drugs (ivermectin, diethylcarbamazine (DEC), and albendazole, or
IDA) is superior to current regimens used in lymphatic filariasis (LF) elimination programs.
IDA may help to accelerate LF elimination in Africa, which has lagged behind other regions.
Although it has not yet been tested, IDA may also be useful for treating onchocerciasis. There
is a serious concern about using DEC in sub-Saharan Africa because of ocular adverse events
after DEC treatment of onchocerciasis in the past. This paper discusses published experience
with DEC in onchocerciasis patients and describes strategies for studying the effects of IDA in
patients with onchocerciasis and LF in Africa.
Introduction
The Global Program to Eliminate Lymphatic Filariasis (GPELF) has made significant progress
in many countries. GPELF has delivered 5,600 million treatments to more than 763 million
people living in 61 countries between the years 2000 and 2014, and it was estimated to have
prevented 36 million clinical cases and saved 175 million disability adjusted life years (DALYs)
[1]. Although elimination of LF is a major goal of the London Declaration on Neglected Tropi-
cal Diseases (NTDs), it is unlikely that LF will be eliminated by the target year of 2020 [2]. The
key strategy of the elimination program comprises repeated annual rounds of mass drug
administration (MDA) to populations at risk of acquiring the infection with diethylcarbama-
zine (DEC) plus albendazole outside of Africa and with ivermectin plus albendazole in Africa
[3]. MDA reduces microfilariae (Mf) in human blood that are necessary for transmission by
mosquito vectors, and one aim of the program is to interrupt transmission. Repeated rounds
of MDA are required because current regimens fail to kill all adult worms and completely clear
Mf following single-dose treatments. Successful programs have sustained annual MDA with
high compliance for several years. Seventy-three countries were considered to be endemic for
LF in 2015, and 55 of them still required MDA [4]. The GPELF has lagged in sub-Saharan
Africa, where only 2 of 35 LF-endemic countries have stopped MDA and started post-MDA
surveillance. Many countries in this region have either not started MDA or have less than 65%
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005163 January 5, 2017 1 / 10
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Fischer PU, King CL, Jacobson JA, Weil
GJ (2017) Potential Value of Triple Drug Therapy
with Ivermectin, Diethylcarbamazine, and
Albendazole (IDA) to Accelerate Elimination of
Lymphatic Filariasis and Onchocerciasis in Africa.
PLoS Negl Trop Dis 11(1): e0005163. doi:10.1371/
journal.pntd.0005163
Editor: Timothy G. Geary, McGill University,
CANADA
Published: January 5, 2017
Copyright: © 2017 Fischer et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: This work was supported by a grant of
the Bill & Melinda Gates Foundation (GH5342). The
findings and conclusions contained within are
those of the authors and do not necessarily reflect
positions or policies of the Bill & Melinda Gates
Foundation. The funders advised on the design of
the study, had no role in data collection and
analysis, had no role in decision to publish, and
contributed in the writing of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
geographical coverage. Hence, a more effective treatment strategy could have a major impact
on LF elimination in Africa.
The goal of onchocerciasis intervention in Africa has also shifted in recent years from con-
trol towards elimination [5, 6]. As with LF, the key strategy for onchocerciasis intervention is
MDA. In most countries, this is accomplished with annual community-directed treatment
with ivermectin (CDTi). Modeling studies predict that current strategies will permit many
countries to reach targets for stopping MDA for onchocerciasis by 2028, but intervention is
likely to be required for a much longer period in some areas (especially in Central Africa) [7].
While annual or semiannual CDTi for 15 to 17 years eliminated the infection in some areas, it
was not sufficient to stop transmission in others [8, 9]. Therefore, extensive research is cur-
rently ongoing to identify drugs that are more effective than ivermectin. Drug development
studies are time and resource intensive, and it is unlikely that a novel drug for onchocerciasis
will be registered to significantly advance the progress of onchocerciasis elimination within
the next 5 years.
In this paper, we discuss the potential value of combination therapy with three currently
approved drugs (ivermectin, DEC, and albendazole, or IDA) for advancing LF and onchocer-
ciasis elimination programs in Africa. Because DEC treatment can cause ocular adverse events
in persons with heavy Onchocerca volvulus infections, studies of the new combination will
have to be conducted with proper precautions. Therefore, this paper also discusses prior expe-
rience with DEC in onchocerciasis patients and a strategy for studying the effects of IDA in
patients with onchocerciasis.
Ivermectin, DEC, and Albendazole (IDA) Treatment for Lymphatic
Filariasis
Thomsen et al. have recently reported that a single dose of coadministered IDA was superior
to the standard two-drug regimen of DEC with albendazole for clearing Wuchereria bancrofti
Mf in infected subjects in Papua New Guinea [10]. All 12 of the heavily infected subjects
treated with IDA had complete clearance of Mf one year after treatment, whereas only 1 of 12
subjects treated with DEC plus albendazole had complete clearance of Mf at 12 months. In
addition, all 6 IDA-treated subjects retested at 24 months were still Mf negative at that time.
This suggests that a single dose of IDA either kills or permanently sterilizes adult W. bancrofti
worms and prevents their hosts from contributing parasites for transmission by mosquitoes.
The Thomsen et al. study also showed that IDA was safe and that there were no significant
interactions between the drugs in the IDA regimen. Early results from larger clinical trials of
IDA in Papua New Guinea and Cote d’Ivoire are consistent with the results reported by Thom-
sen et al. These results suggest that IDA has the potential to dramatically accelerate LF elimina-
tion programs. Several large community trials are underway to confirm the safety and efficacy
of IDA in different epidemiological settings. Because DEC has the potential to cause ocular
adverse events in individuals infected with O. volvulus, all of these studies are being conducted
in areas without coendemic onchocerciasis.
IDA for LF Elimination in Areas Not Coendemic for Onchocerciasis
Although most sub-Saharan countries endemic for LF use ivermectin combined with albenda-
zole in their elimination programs, the region includes also countries or areas that are nonen-
demic for onchocerciasis or loiasis (e.g., Kenya, Zanzibar, Comoros, Sao Tome and Principe,
Eritrea, Madagascar, Zambia, and Zimbabwe), and these countries currently use or plan to use
DEC combined with albendazole in their LF elimination programs [11]. These countries stand
to immediately benefit from the more effective IDA regimen if results from ongoing safety
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trials are favorable. For other countries, we need to consider how IDA might be used for LF
elimination in areas without coendemic onchocerciasis. In some countries (e.g., Tanzania)
onchocerciasis foci are limited and geographically separated from LF-endemic areas, and IDA
might be used to eliminate LF in these areas at the district level. However, this strategy requires
accurate disease maps, careful assessment of human migration patterns, an ability to safely
screen out individuals that may be at risk of onchocerciasis, and an understanding of the
effects and adverse events associated with DEC treatment of onchocerciasis.
Efficacy and Safety of DEC for Treatment of Onchocerciasis
Diethylcarbamazine (N, N-diethyl-4-methyl-1-piperazine carboxamide) was shown to be
effective against filarial parasites in the late 1940s [12–15]. Although it was recognized early
that DEC can cause adverse reactions in individuals infected with O. volvulus, it was the rec-
ommended first line treatment for onchocerciasis for about 40 years because better alternatives
were not available until ivermectin was introduced [16–18]. A treatment course of oral DEC
was used for both individual and community treatment [19]. In addition, topical DEC or eye
drops containing DEC were sometimes used to specifically target skin or ocular disease,
respectively [20–22]. Since eye lesions were among the most severe clinical signs of O. volvulus
infection, people with ocular involvement were often preferentially treated [23]. DEC was
administered in multiple doses, and many different dosing regimens were evaluated (Table 1).
One common regimen recommended for a 50 kg adult was a total dose of 1,350 mg over eight
days (average total dose per course of 27 mg/kg body weight), with a low dose of 1 mg/kg on
day one and higher doses thereafter. Patients were often treated with a second course of DEC
four months later [16]. The efficacy and safety of single-dose treatment with DEC (6 mg/kg)
combined with albendazole (400 mg) used for elimination of LF outside Africa was never eval-
uated in patients with onchocerciasis because of the risk of inducing Mazzotti reactions and
ocular adverse events in Mf-positive individuals and because ivermectin was much better tol-
erated. DEC-fortified cooking salt that is sometimes used for LF intervention was reported to
be safe but not effective in subjects with onchocerciasis [24].
After many years of DEC use for onchocerciasis, reports indicated that this treatment could
cause new ocular lesions or worsen preexisting onchocercal eye disease (Table 1) that included
not only the anterior segment of the eye (cornea and anterior chamber) but also the posterior
segment (with chorioretinitis and optic nerve atrophy) [18, 25–29]. During the 1980s, a single
dose of ivermectin was shown to be more effective than DEC for clearing O. volvulus Mf from
the skin, and ivermectin treatment did not cause ocular adverse events [25, 29–31]. It should
be noted that adverse events after DEC treatment correlated with the Mf density in the skin
and with the presence of Mf in the eye (cornea, anterior chamber, retina) [32]. A review of ten
clinical studies with varying dosing regimens indicated that DEC was usually well tolerated in
individuals with low Mf densities of less than 10 Mf/mg skin [16]. However, one study showed
that worsening eye disease was associated with the presence of circulating immune complexes
in serum prior to and during treatment when patients were treated with high doses and pro-
longed courses of DEC (150 mg per week for eight weeks, 200 mg per week for four months
after an initial course of 1,100 mg over eight days) [33].
Results of clinical and preclinical studies suggest that the host’s immune response is impor-
tant for DEC and ivermectin efficacy. However, the nature of these interactions is not fully
understood [34, 35]. Both drugs have different molecular targets and different dynamics of Mf
clearance. After DEC treatment, some O. volvulus Mf are released into the bloodstream. How-
ever, most Mf stay in the skin, where they are attacked by eosinophils and other effector cells
and cause a local skin reaction [36]. In contrast, after treatment with ivermectin, Mf are rapidly
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cleared from the skin and degraded in peripheral lymph nodes [37, 38]. Although both drugs
are assumed to have no macrofilaricidal or permanent sterilizing effects on O. volvulus adult
worms, synergistic effects as observed in W. bancrofti are possible [10, 39]. This hypothesis
should be tested with future research.
The Case for Investigating IDA for Onchocerciasis
Ivermectin is currently widely used for control and elimination of onchocerciasis. A single
150 μg/kg dose usually clears skin Mf and causes temporary sterility for about three to four
months, after which Mf newly released from female worms repopulate the skin. The related
drug moxidectin (8 μg/kg) clears skin Mf for about twice as long, but the drug is not yet
approved for human use [40]. If IDA is as effective against O. volvulus adult worms as it
Table 1. Selected studies that report adverse events of onchocerciasis patients after treatment with DEC compared with a potential study design
of IDA.
Location/Type of the
study
Participant characteristics DEC dosing Adverse events in DEC group Reference
Liberia/randomized
clinical trial (RCT) oral/
topical
Ten men; mean Mf 7 Mf/mg skin; no
obvious eye disease
1,100 mg over eight
days, ~5,450 mg over
six months, total about
109 mg/kg
Initial Mazzotti* reaction; Fluffy corneal
opacities in nine patients first detected seven
days after beginning of treatment, other
ocular changes, no follow-up after conclusion
of treatment
[28]
Southern Sudan/
observational
18 men; >50 Mf/mg; no acute eye disease,
but ocular Mf
925 mg over eight
days, total ~15 mg/kg
Mazzotti reaction in all patients; new ocular
lesions (some transient, some sustained) in
most patients starting two days after
beginning of treatment, no assessment after
treatment
[26]
Liberia/randomized
observational
Ten men; low to moderate skin Mf 1,100 mg over eight
days, ~5,450 mg over
six months, total about
109 mg/kg
Initial Mazzotti reaction; Anterior uveitis in
most patients, some patients with
chorioretinitis, optic nerve pallor, visual field
constriction, adverse events associated with
circulating immune complexes, no follow-up
after conclusion of treatment
[33]
Northern Ghana/
observational
21 men; varying skin Mf density, no eye
assessments
200 mg/day for seven
days, total ~23 mg/kg
Mazzotti reaction, severe pruritus,
lymphadenopathy, and hypotension related to
Mf density
[32]
Mali/placebo-controlled
RCT with ivermectin
arm
Ten men; ~100 Mf/mg; 70% punctate
keratitis, 50% Mf in the anterior chamber
1,300 mg over eight
days, total ~22 mg/kg
50% with mild to moderate Mazzotti reaction,
50% with severe Mazzotti; ocular findings
unchanged, only one patient with new ocular
lesions at six months
[51]
Liberia/placebo-
controlled RCT with
ivermectin arm
Ten men; ~ 40 mf/mg; 90% with eye
disease and/or ocular Mf
1,300 mg over eight
days, total ~22 mg/kg
Mazzotti reaction, adverse reaction score
twice as high as in ivermectin group;
increased punctate opacities starting four
days after beginning of treatment, ocular
changes resolved by six months after
treatment
[29, 30]
Northern Ghana/
controlled RCT with
ivermectin versus
placebo
17 men; moderate to heavy O. volvulus
infection (~112 mf/mg), 88% with ocular Mf
1,300 mg over eight
days, total ~22 mg/kg
Mazzotti reaction; increased punctate corneal
opacities starting four days after begin of
treatment that were resolved by six months
[52]
Proposed RCTs with
IDA versus ivermectin
Ivermectin pretreatment 3 months before
IDA. For those with zero Mf in the skin or
eye three months later, randomize to treat
with IDA or with ivermectin alone at time
zero months.
Single IDA treatment
contains DEC (6 mg/
kg)
Follow-up skin Mf at 6, 12, 18, and 24 months.
Adult worms assessed by nodulectomy at 24
months
*Mazzotti reactions may include fever, pruritus, skin rash, headache, arthralgia, and painful lymphadenopathy.
doi:10.1371/journal.pntd.0005163.t001
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appears to be against W. bancrofti, it might permanently sterilize the adult worms and perma-
nently clear Mf from the skin. If it is effective, IDA treatment could also be useful in areas that
have had suboptimal responses to ivermectin alone [41].
These considerations strongly support the idea of conducting randomized clinical trials
(RCT) to assess the efficacy and adverse event profiles of IDA compared with ivermectin alone
in persons with onchocerciasis. The studies will have to be carefully designed to avoid ocular
adverse events that have been associated with DEC in the past. However, as mentioned above,
the use of single-dose IDA to treat onchocerciasis is fundamentally different from the histori-
cal use of DEC therapy for onchocerciasis. Previously, the major goal of DEC treatment was to
reduce Mf counts in patients with clinically manifest eye or skin disease and heavy infections
by administering DEC for a week or longer. In contrast, the objective of IDA trials in Africa
would be to assess IDA’s safety and efficacy as a single-dose regimen for long term clearance of
Mf from the skin.
A protocol for clinical trials of IDA in onchocerciasis might include the following features:
All participants in the trial should have an ophthalmological assessment prior to enrollment to
rule out ocular disease. They should also have Mf present in skin snips and palpable nodules.
Participants should all be pretreated with standard dose ivermectin (or ivermectin plus alben-
dazole in areas coendemic for LF). Skin snip testing should be repeated and eye exams should
be performed 3 months after treatment. Individuals eligible for the RCT should have no Mf in
their eyes by slit lamp examination and zero Mf in skin snips at that time. Participants would
then be randomized to receive either ivermectin alone (ivermectin plus albendazole in areas
with coendemic LF) or IDA. Participants would be carefully monitored for adverse events by
clinicians who are unaware of their treatment assignments. The main efficacy endpoint would
be long-term clearance of Mf from the skin as assessed by microscopy and PCR of skin snips.
This will be assessed at 6-month intervals for at least 24 months. A secondary endpoint for
onchocerciasis IDA studies would be assessment of macrofilaricidal and/or long-lasting
embryostatic effects of the treatment by histological examination of adult worms in excised
nodules [42]. Safety assessments for IDA in onchocerciasis will include careful monitoring for
adverse events following treatment, and this will include repeated ophthalmological
examinations.
If RCTs show that IDA is safe and more effective for long-term suppression of Mf than iver-
mectin alone, the next step would be to perform community trials. Protocol details will need
to be developed and carefully reviewed by institutional review boards before studies can be ini-
tiated. However, we think it is useful to present a draft outline as a starting point for discussion:
Community trial participants would be pretreated with ivermectin or ivermectin plus albenda-
zole and given a “treatment card” to document pretreatment. Three months later, persons
with documented pretreatment would be offered treatment with either ivermectin alone or
with IDA, and participants would be retested to assess reappearance of Mf in the skin at 12
and 24 months. Persons with Mf in skin snips at 12 months would be retreated with the stan-
dard regimen used in their region at that time (ivermectin or ivermectin plus albendazole).
The primary endpoints for the study would be percentages of study participants with negative
skin snip examinations for Mf at 12 and 24 months. The absence of O. volvulus DNA in skin
snips by PCR would be a useful secondary endpoint.
Progress of Onchocerciasis Control Sets the Stage for Potential
Use of IDA in Africa
The epidemiological situation of onchocerciasis has dramatically changed since the era of
widespread DEC use in the 1960s and 70s. Onchocerciasis is believed to be eliminated from
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most savanna areas in West Africa where blinding onchocerciasis was highly prevalent in the
past [43, 44]. Persisting foci of onchocerciasis mainly occur in forested regions of West and
Central Africa, where blinding onchocerciasis is not common [45]. Community-directed treat-
ment using ivermectin in hyper- and mesoendemic foci has reduced Mf prevalence and den-
sity considerably in the countries of the former African Program for Onchocerciasis Control
[46]. However, many of these areas still require ivermectin because of the continuing presence
of viable adult female worms that cause low-level microfiladermia (usually less than 5 Mf/mg
skin) with little or no eye involvement. These would be suitable areas for community studies of
IDA if RCTs have shown that the regimen is safe and effective for treatment of onchocerciasis.
The new push for onchocerciasis elimination will also extend mass treatment into hypoen-
demic areas where Mf rates are less than 20%. The danger of DEC in such areas is likely to be
relatively low but not zero because some untreated individuals in hypoendemic areas may
have high skin Mf counts with ocular Mf or because they have recently moved from hyperen-
demic areas. Therefore, documented ivermectin pretreatment at the level of individuals would
still be required prior to IDA use in such areas.
IDA for LF Elimination in Areas Coendemic for Onchocerciasis
The proposed IDA RCTs in persons infected with O. volvulus may serve a dual purpose: First,
they may demonstrate that IDA can be safely used for LF elimination in areas that are coen-
demic for onchocerciasis (Fig 1). Second, they may show that IDA is more effective than iver-
mectin alone for treatment of onchocerciasis. If preliminary studies show that IDA can be
safely used in persons with onchocerciasis following pretreatment with ivermectin, then it
potentially could be used in large parts of Africa that are currently using or plan to use iver-
mectin combined with albendazole for LF elimination. Although we hope that IDA will be
superior to ivermectin alone for onchocerciasis, this need not be the case for IDA to be useful
for LF elimination programs in areas of Africa with coendemic onchocerciasis.
Risk and Benefit Considerations of IDA for Onchocerciasis
Carefully designed IDA RCTs in individuals with onchocerciasis will have a low but manage-
able risk. On the other hand, IDA’s potential benefit is huge because it could significantly
accelerate elimination of both LF and onchocerciasis in Africa. It is also possible that IDA will
not be safe enough for use as MDA in most regions of Africa. But this possibility should not
prevent performance of RCTs for onchocerciasis because a therapy that cannot be used for
MDA may still be useful for individual case management. We believe it is likely that a single
dose of IDA (administered several months following an Mf-clearing dose of ivermectin) will
be much more effective for long-term clearance of O. volvulus Mf than ivermectin alone. We
call this strategy “pretreat and treat.” It is also possible that IDA will kill or permanently steril-
ize adult female O. volvulus worms. These hypotheses must be tested because IDA has the
potential to completely change the game for onchocerciasis as it is likely to do for LF.
One challenge to be considered early is the risk of uncontrolled use of DEC in countries
where it is not currently used because of safety concerns. This should not be a problem for
clinical or community trials because DEC would only be used per protocol by trained person-
nel, and the remaining drug would be removed and destroyed by the research teams. If
research studies show that IDA can be safely used with “pretreat and treat” or with other strat-
egies in areas with onchocerciasis, DEC should only be licensed for use by national MDA pro-
grams. Any regulatory barriers and restrictions for the use of DEC in onchocerciasis-endemic
countries would need to be addressed through the studies and policy change would need to be
supported by robust data.
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Evaluation of IDA for Other Filarial Infections in Africa
Of course, W. bancrofti and O. volvulus are not the only human filarial parasites that occur in
Africa that could be affected by IDA. At present, there is no effective single-dose treatment for
Mansonella perstans, which may be the most abundant and widespread filarial parasite in
Africa [47]. Therefore, it would be important to perform trials to assess the safety of IDA in
persons infected with M. perstans, and these studies would also assess whether IDA is an effec-
tive single-dose treatment for this infection. This would be important so that any rollout of
IDA for use in LF or onchocerciasis elimination programs would not be limited by the pres-
ence of M. perstans. Because Mansonella streptocerca has a limited geographical distribution,
usually produces low Mf densities, and is highly susceptible to both DEC and ivermectin, IDA
is likely to be safe for use in persons with that infection.
Coendemic loiasis is currently a major barrier to Lf and onchocerciasis elimination in some
parts of Africa because ivermectin can lead to serious adverse events including coma and
death in patients with high Loa loa Mf densities [48]. Neurological serious adverse events have
also been described after DEC in subjects with high L. loa Mf densities [49]. IDA (which con-
tains ivermectin and DEC) is also very likely to be unsafe in individuals with high L. loa Mf
counts. Currently, a test and treat strategy is being evaluated in which individuals are screened
for L. loa, and persons with high blood Mf counts are excluded from MDA with ivermectin
[50]. A similar approach could be considered for a clinical trial to explore the value of IDA
Fig 1. Clinical signs of onchocerciasis (A) and lymphatic filariasis (B) in the same individual living in an area coendemic for both infections in Lofa
County, Liberia. A Hypopigmented skin (“leopard skin”) on the shins. B Advanced hydrocele.
doi:10.1371/journal.pntd.0005163.g001
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005163 January 5, 2017 7 / 10
treatment for individuals with loiasis plus either LF or onchocerciasis. Persons with high L. loa
Mf counts who cannot be treated with ivermectin would be excluded from the study. Persons
with lower L. loa Mf counts could be pretreated with ivermectin alone and later randomized to
receive either ivermectin alone or IDA when L. loa Mf counts are zero or very low. Beyond the
safety issue regarding treatment of LF and onchocerciasis in central Africa, IDA (following a
clearing dose of ivermectin) has the potential to be the first effective single-dose treatment for
loasis, which is itself of clinical significance. Of course, any new antifilarial drug or combina-
tion will need to be carefully tested before it can be used in areas that are highly endemic for
loiasis.
Conclusions
IDA has the potential to be a game changer for LF elimination in Africa, especially in countries
and regions without coendemic onchocerciasis or loiasis. More research is required to deter-
mine if there is a safe and effective way to use IDA in coendemic settings. Additional research
will be needed to test whether IDA is safe and effective for treating onchocerciasis, first in
individuals and later in endemic populations with or without coendemic LF. We are very
enthusiastic about this possibility because IDA is likely to be more effective for clearance and
suppression of Mf than ivermectin alone. Compared to drugs that have not yet been tested in
humans, IDA provides a potential fast-track and low-cost option that could accelerate elimina-
tion of LF and onchocerciasis in Africa.
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